drugset / Trial / NCT06682611
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multi-center, multi-cohort, phase Ib/II clinical trial, divided into 8 cohorts according to tumor types. Cohorts 1-4 are SYHA1813 combined with different regimens, including safety run-in stage and cohort expansion stage. Cohorts 5-8 are SYHA1813 monotherapy and only include the expansion cohorts. The primary objective was to evaluate the safety and efficacy of SYHA1813 single agent or in combination with different regimens in unresectable locally advanced or metastatic solid tumors.
Timeline
- Start
- 2024-11-13
- Primary completion
- 2026-11-13
- Completion
- 2027-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | — |
| Subject | Regorafenib | Small molecule | — | — |
| Subject | SYHA1813 | Unknown | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Enlonstobart | Monoclonal antibody | — | — |
| Comparator | Etoposide | Small molecule | — | — |
| Comparator | HB1801 | Unknown | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
Indications
No indication recorded.